VYNE Therapeutics Inc. (VYNE) Social Stream
VYNE THERAPEUTICS INC (VYNE) Price Targets From Analysts
Use the tables below to see what analysts covering VYNE THERAPEUTICS INC think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-08-16 | 6 | $14 | $3 | $6.666 | $2.55 | 161.41% |
| 2021-11-11 | 6 | $14 | $3 | $6.5 | $2.55 | 154.9% |
| 2021-12-06 | 4 | $14 | $3 | $7.166 | $2.55 | 181.02% |
| 2022-03-21 | 6 | $14 | $3 | $7.166 | $2.55 | 181.02% |
| 2022-04-07 | 5 | $14 | $3 | $7.166 | $2.55 | 181.02% |
| 2022-05-18 | 5 | $10 | $3 | $5.8 | $2.55 | 127.45% |
| 2022-08-10 | 5 | $10 | $1.5 | $4.875 | $2.55 | 91.18% |
| 2022-08-15 | 5 | $5 | $1.5 | $3.625 | $2.55 | 42.16% |
| 2022-10-11 | 6 | $5 | $1.5 | $3.7 | $2.55 | 45.1% |
| 2022-11-11 | 5 | $5 | $1.5 | $3.875 | $2.55 | 51.96% |
| 2023-03-10 | 5 | $89.93 | $26.978 | $69.694 | $2.55 | 2633.1% |
| 2023-03-14 | 5 | $89.93 | $28 | $69.95 | $2.55 | 2643.14% |
The Trend in the Analyst Price Target
Over the past 26 months, VYNE's average price target has gone up $64.26.
Over the past 51 weeks, VYNE's average upside potential has been 3,147.12%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-03-21 | 5 | 14.000 | 3.000 | 7.166 | 0.700 | 923.71% |
| 2022-08-10 | 5 | 10.000 | 1.500 | 4.700 | 0.312 | 1406.41% |
| 2022-08-15 | 5 | 5.000 | 1.500 | 3.625 | 0.320 | 1032.81% |
| 2022-11-11 | 5 | 5.000 | 1.500 | 3.875 | 0.270 | 1335.19% |
| 2022-11-11 | 5 | 89.928 | 26.978 | 69.694 | 0.270 | 25712.59% |
VYNE Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.4 | 4 | 0 | 1 | 0 | 0 | 5 |
The Trend in the Broker Recommendations
VYNE's average broker recommendation rating worsened by 0.07 over the prior 151 days.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for VYNE as an investment opportunity.
- In the context of all US stocks, VYNE THERAPEUTICS INC's variance in analysts' estimates is lower than -1273.28% of them.
- To contextualize these metrics, consider that out of all US stocks, VYNE THERAPEUTICS INC's average analyst price target is greater than 247.29% of them.
- In terms of how VYNE THERAPEUTICS INC fares relative to stocks in the small market cap category, note that its upside potential (average analyst target price relative to current price) is higher than 863.68% of that group.
- In terms of how VYNE THERAPEUTICS INC fares relative to Healthcare stocks, note that its number of analysts covering the stock is higher than 493.64% of that group.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to VYNE THERAPEUTICS INC are CUE, ENSC, and NRXP.
View All Top Stocks by Price Target
Make investment decisions regarding VYNE using the data that counts. Try POWR Ratings for free.